217 related articles for article (PubMed ID: 22892454)
21. Augmented CD3(+)CD8(+) and CD3(+)CD56(-) cells in cytokine-induced killer cells cultured with engineered cells for costimulatory enhancement from heavily pretreated patients with solid tumor.
Wang L; Yi Y; Yin D; Zhou Z; Fan J; Ye W; Zhao W
Cytotherapy; 2016 Apr; 18(4):581-9. PubMed ID: 26971686
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
23. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants.
Gritzapis AD; Dimitroulopoulos D; Paraskevas E; Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2002 Oct; 51(8):440-8. PubMed ID: 12202905
[TBL] [Abstract][Full Text] [Related]
24. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
[TBL] [Abstract][Full Text] [Related]
25. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
26. Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells.
Zanon C; Stocchero M; Albiero E; Castegnaro S; Chieregato K; Madeo D; Rodeghiero F; Astori G
Cytometry B Clin Cytom; 2014 Jul; 86(4):257-62. PubMed ID: 24002818
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models.
Zheng Y; Hu B; Xie S; Chen X; Hu Y; Chen W; Li S; Hu B
Cytotherapy; 2017 May; 19(5):617-628. PubMed ID: 28215653
[TBL] [Abstract][Full Text] [Related]
28. Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.
Wang J; He M; Shi W; Sha H; Feng J; Wang S; Wang Y
Cancer Invest; 2009 Mar; 27(3):244-50. PubMed ID: 19194830
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells.
Lin G; Wang J; Lao X; Wang J; Li L; Li S; Zhang J; Dong Y; Chang AE; Li Q; Li S
J Immunother; 2012 May; 35(4):337-43. PubMed ID: 22495391
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
[TBL] [Abstract][Full Text] [Related]
32. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells.
Wongkajornsilp A; Sangsuriyong S; Hongeng S; Waikakul S; Asavamongkolkul A; Huabprasert S
J Orthop Res; 2005 Nov; 23(6):1460-6. PubMed ID: 15908161
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
[TBL] [Abstract][Full Text] [Related]
34. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
35. Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro.
Ahn YO; Kim S; Kim TM; Song EY; Park MH; Heo DS
J Immunother; 2013 Sep; 36(7):373-81. PubMed ID: 23924789
[TBL] [Abstract][Full Text] [Related]
36. Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratio.
Mercier-Letondal P; Montcuquet N; Sauce D; Certoux JM; Jeanningros S; Ferrand C; Bonyhadi M; Tiberghien P; Robinet E
Cytotherapy; 2008; 10(3):275-88. PubMed ID: 18418773
[TBL] [Abstract][Full Text] [Related]
37. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
38. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells.
Li Y; Schmidt-Wolf IG; Wu YF; Huang SL; Wei J; Fang J; Huang K; Zhou DH
Anticancer Res; 2010 Sep; 30(9):3493-9. PubMed ID: 20944128
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
40. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]